Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors
January 20, 2022 08:30 ET
|
Elpiscience Biopharmaceuticals, Inc.
SHANGHAI, China and SUZHOU, China and GERMANTOWN, Md., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company...
Elpiscience to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 06, 2022 09:00 ET
|
Elpiscience Biopharmaceuticals, Inc.
SHANGHAI, China and SUZHOU, China and GERMANTOWN, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company...